Category: nuclear medicine tests
Neuroendocrine Tumors Featured in Society of Nuclear Medicine and Molecular Imaging 2014 Meeting
Josh Mailman, President of the NorCal CarciNET Community and Chair of the Patient Advocacy Advisory Board for the Society of Nuclear Medicine and Molecular Imaging (SNMMI), will give the Welcome presentation for the SNMMI Patient Education Day on June…
READ MORE
1st World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy (PRRNT)
Since 1997, when he first used the radiolabeled peptide Y-90 DOTATOC (a somatostatin analogue) to treat a 15-year-old boy with a rare neuroendocrine tumor, called paraganglioma, and saw the boy go from being wheelchair-bound and in terrible pain to …
READ MOREImportant Octreoscan Update for U.S. & Canadian Carcinoid/NETs Patients
Octreoscans are again available in the United States and Canada! Production has resumed for Covidien’s Octreoscan Kit using Indium In-111 pentetreotide.…
READ MOREOctreoscan Test for Carcinoid & NET Patients Currently on Hold in U.S. and Canada
Due to a voluntary recall by the drug company Covidien, the Octreoscan Kit using Indium In-111 pentetreotide is not available at the present time in the United States or Canada. This means that carcinoid and neuroendocrine tumor patients cannot have…
READ MORE
